Dr. Choueiri on results of KEYNOTE-564 trial of adjuvant pembrolizumab in RCC

Toni K. Choueiri, MD, discusses results from the phase 3 KEYNOTE-564 trial presented during the 2021 ASCO Annual Meeting. The study explored pembrolizumab versus placebo following nephrectomy in patients with clear cell renal cell carcinoma.

Choueiri is director of the Lank Center for Genitourinary Oncology, director of the Kidney Cancer Center, and senior physician at Dana-Farber Cancer Institute, as well as Jerome and Nancy Kohlberg chair and professor of medicine at Harvard Medical School.